Literature DB >> 16442075

Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.

T Shantha Raju1, Bernard J Scallon.   

Abstract

IgG antibodies (Abs) and fragments of IgG Abs are becoming major biotherapeutics to treat an assortment of human diseases. Commonly prepared fragments of IgGs include Fc, Fab, and F(ab')2 fragments, all of which can be made using the sulfhydryl protease papain, although prolonged digestion times and/or excessive amounts of papain typically result in further cleavage of the Fc domain into smaller fragments. During our attempts to use papain to isolate Fc fragments from different IgG monoclonal Abs, it was observed that prior removal of Fc glycans resulted in a faster rate of papain-mediated degradation of the Fc domain. Subsequent time-course experiments comparing glycosylated and deglycosylated versions of IgG antibodies showed that the majority of molecules in a deglycosylated IgG sample were converted into Fab, Fc, and smaller Fc fragments in less than one hour, whereas the original glycosylated IgG required more than two hours to convert into a comparable amount of Fab and Fc fragments. Furthermore, whereas papain digestion converted almost all of a deglycosylated Fc fragment into smaller fragments of approximately 10 and approximately 12 kDa within 4 h, more than 40% of a glycosylated Fc fragment remained intact even after 24 h of digestion. These results indicate that the presence of CH(2) domain glycans in either IgGs or purified Fc fragments increases resistance to papain digestion. Increased sensitivity of non-glycosylated Fc domains to papain is consistent with the Fc domains lacking a defined structure, as exemplified by their inability to bind Fcgamma receptors, since misfolded proteins are often degraded by proteases because of increased accessibility of their proteolytic cleavage sites. Based on these observations it is possible to use papain sensitivity as a means of assessing proper Fc structure of IgG molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442075     DOI: 10.1016/j.bbrc.2006.01.030

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  2D (1)H(N), (15)N Correlated NMR Methods at Natural Abundance for Obtaining Structural Maps and Statistical Comparability of Monoclonal Antibodies.

Authors:  Luke W Arbogast; Robert G Brinson; Trina Formolo; J Todd Hoopes; John P Marino
Journal:  Pharm Res       Date:  2015-10-09       Impact factor: 4.200

4.  Remarkable transglycosylation activity of glycosynthase mutants of endo-D, an endo-β-N-acetylglucosaminidase from Streptococcus pneumoniae.

Authors:  Shu-Quan Fan; Wei Huang; Lai-Xi Wang
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

5.  Galactosylation variations in marketed therapeutic antibodies.

Authors:  T Shantha Raju; Robert E Jordan
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 6.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

7.  High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

Authors:  Mohammad A Alsenaidy; Jae Hyun Kim; Ranajoy Majumdar; David D Weis; Sangeeta B Joshi; Thomas J Tolbert; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-09-24       Impact factor: 3.534

8.  Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.

Authors:  Kai Zheng; Mark Yarmarkovich; Christopher Bantog; Robert Bayer; Thomas W Patapoff
Journal:  MAbs       Date:  2014-03-24       Impact factor: 5.857

9.  Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.

Authors:  Wei Huang; John Giddens; Shu-Quan Fan; Christian Toonstra; Lai-Xi Wang
Journal:  J Am Chem Soc       Date:  2012-07-16       Impact factor: 15.419

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.